BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 13, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2006

View Archived Issues

Novel selective Aurora A kinase inhibitors developed at Cyclacel

Read More

Talotrexin pharmacokinetics determined in non-small lung cancer patients

Read More

Preclinical and phase I results reported for PTC-299

Read More

Bionomics reports recent progress

Read More

MorphoSys and Boehringer Ingelheim expand collaboration into cancer

Read More

Milestone in Nautilus and Creabilis Therapeutics' collaboration

Read More

Ono rounds up domestic and overseas developments

Read More

TAK-475 compared with and added to atorvastatin

Read More

D-4F improves HDL inflammatory function in coronary heart disease patients

Read More

DISPERSE studies show consistent platelet aggregation inhibition with AZD-6140

Read More

RSD-1235 effective in patients on rate- or rhythm-control medications

Read More

Darusentan lowers blood pressure in patients taking multiple therapies

Read More

Two-year study data show sustained benefit of abatacept in rheumatoid arthritis

Read More

Rheumatoid arthritis responses to golimumab maintained for 1 year

Read More

Oglufanide studied for hepatitis C in Australian trial

Read More

Fast track status for Ceflatonin in CML

Read More

ALTU-135 to begin phase III trial for cystic fibrosis in Q2 2007

Read More

Fast track designation for STA-4783 in metastatic melanoma

Read More

Recent patents disclose novel antiinfective agents

Read More

ALT-2074 reduces myocardial damage in diabetic mice

Read More

Agents for atherosclerosis, pulmonary hypertension patented

Read More

Pharmion acquires Cabrellis

Read More

Medivation outlines plans for key programs

Read More

Patents reveal novel agents for ulcer, inflammatory bowel disease, etc.

Read More

VEC-162 shows ability to induce and maintain sleep

Read More

ISA-247 shows good efficacy, maintains good kidney function in transplant patients

Read More

Vascugel is safe in phase I trials

Read More

Preclinical data on lead kinase compounds from SuperGen reported

Read More

Emerging companies showcased at BIO-Europe 2006: ACE BioSciences

Read More

Herceptin approved for adjuvant treatment of HER2+ node-positive breast cancer

Read More

Angiotech seeks CE Mark for Vascular Wrap product

Read More

Scientists track lung carcinogenesis in exhaled breath

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 13, 2026.
  • Brain maze

    Alzheimer’s, beyond the brain

    BioWorld
    Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 12, 2026
  • Hantavirus zoonotic spillover illustration

    First cruise ship hantavirus genome points to zoonotic spillover

    BioWorld
    The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a passenger on the cruise ship MV...
  • Test tubes, dropper and capsules

    Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

    BioWorld
    In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing